PanOptica Inc.
This article was originally published in Start Up
Executive Summary
The founders of PanOptica are inspired by the big impact VEGF-inhibitors originally developed for cancer are having on the ophthalmic market. So much so, that they company aims to search out compounds from other disease areas such as cancer, diabetes and other metabolic disorders, and find those likely to have potential for serious eye disorders.
You may also be interested in...
Start-Up Quarterly Statistics, Q1 2011
Biopharma and medical device start-ups brought in a total of $216 million in Q1 2011. Absent were any financings involving in vitro diagnostics companies. Only four acquisitions involving start-ups were completed - one in biopharma and three in the device industry. Cancer was the most popular therapeutic category among biopharma start-up alliance this quarter.
Start-Up Quarterly Statistics, Q1 2011
Biopharma and medical device start-ups brought in a total of $216 million in Q1 2011. Absent were any financings involving in vitro diagnostics companies. Only four acquisitions involving start-ups were completed - one in biopharma and three in the device industry. Cancer was the most popular therapeutic category among biopharma start-up alliance this quarter.
Start-Up Previews (02/2011)
A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Emerging MS Treatments: Reading the Gilenya Tea Leaves," includes profiles of Allozyne, GeNeuro, Nuron Biotech and Receptos. Plus these Start-Ups Across Health Care: Intralink-Spine, NinePoint Medical, PanOptica and Urovalve.